In summary, our preclinical studies show that HER2 or EGFR hCART41BBζ can effectively kill multiple tumor targets, kill tumor targets in sequential and serial killing assays, secrete Th1 cytokines and chemokines and exhibit specific target killing in in vitro hypoxic condition. This evidence concerns the gene EGFR and neoplasm.